
    
      This study was an extension study conducted as an open-label multicenter study in rheumatoid
      arthritis (RA) participants who completed the Phase IIb Study of ASP015K [015K-CL-RAJ1
      (hereinafter referred to as study RAJ1)], Phase III Study of ASP015K [015K-CL-RAJ3 (RAJ3)],
      or Phase III Study of ASP015K [015K-CL-RAJ4 (RAJ4)]. After the marketing approval in Japan on
      26 Mar 2019, this study continued as "post marketing clinical study" in Japan. In Taiwan and
      Korea, this study continued as "clinical study".

      Participants received oral ASP015K once daily (QD) after breakfast. The ASP015K dose was
      increased later for participants who have no safety problems but showed lack of efficacy.

      The duration of treatment with the study drug was differed depending upon the participants.
    
  